CorMedix (CRMD) to Release Quarterly Earnings on Thursday

CorMedix (NASDAQ:CRMD) will be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

CorMedix (NASDAQ:CRMD) last released its earnings results on Tuesday, March 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). On average, analysts expect CorMedix to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CorMedix Price Performance

Shares of NASDAQ CRMD opened at $5.84 on Wednesday. The stock’s 50-day moving average is $4.57 and its two-hundred day moving average is $3.81. The company has a market cap of $320.10 million, a price-to-earnings ratio of -6.35 and a beta of 1.79. CorMedix has a 1-year low of $2.57 and a 1-year high of $7.00.

Insider Transactions at CorMedix

In related news, CEO Joseph Todisco bought 13,561 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were purchased at an average cost of $3.74 per share, with a total value of $50,718.14. Following the transaction, the chief executive officer now directly owns 352,839 shares of the company’s stock, valued at approximately $1,319,617.86. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CRMD. JMP Securities reiterated a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a research note on Tuesday, April 9th. Royal Bank of Canada lowered their target price on shares of CorMedix from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Wednesday, March 13th. Truist Financial cut their price target on CorMedix from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, January 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of CorMedix in a report on Tuesday, April 9th.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.